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Abstract
This case report presents ﬂuoconazole efﬁcacy to reduce hypercalcaemia and increased urinary calcium excretion in a patient
with nephrocalcinosis after a long history of recurrent renal stones caused by a loss-of-functionmutation of the CYP24A1 gene.
The CYP24A1 gene codes for a key enzyme in the vitamin D endocrine system that protects against vitamin D toxicity by
degrading the circulating excess of both 1,25-dihydroxyvitamin D, the hormonal form of vitamin D, and its precursor,
25-hydroxyvitamin D. In order to expedite the identiﬁcation of this rare disorder and improve therapies to avoid its progression
to nephrocalcinosis, this editorial updates the current knowledge on the frequency of CYP24A1-inactivating mutations, the
features of their early clinical presentation and progression, and the pathophysiology of vitamin D activation in health and in
granulomatous disorders that may help improve current treatment.
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The integrityof thevitaminDendocrinesystemisessential tomain-
tain serum calcium levels within the narrow limits required to pro-
tect individuals from the adverse effects of hypercalcaemia and
increased urinary calcium excretion, which increase the propensity
for kidney stones, nephrocalcinosis and renal insufﬁciency [1, 2].
Figure 1 summarizes the current understanding of the tight
systemic and local control of vitamin D activation, inactivation
and biological actions. The vitamin Dhormone 1,25-dihydroxyvi-
tamin D (1,25D) is the most potent endogenous activator of the
vitamin D receptor (VDR) to exert the plethora of vitamin D bio-
logical actions, including themaintenance ofmineral homeostasis
and skeletal health. However, recent studies in Cyp27b1-null mice
[3, 4], which lack the enzyme that converts 25-hydroxyvitamin D
(25D) to 1,25D, and also in vitro, using 25D analogues chemically
modiﬁed to prevent their 1-hydroxylation, have demonstrated
that 25D can activate the VDR directly and can also synergize
with 1,25D for VDR activation.
Importantly, many cells possess CYP27A1 and CYP2R1, the
two main cytochrome P450s that convert vitamin D to 25D.
Since this reaction is very loosely regulated, it is clear that a
tight regulation of 25D conversion to 1,25D is essential to main-
tain serum 1,25D within the narrow limits required to avoid
hypercalcaemia.
For many years, it was believed that 1,25D tightly controlled
its own levels through dual mechanisms: suppressing its own
synthesis and stimulating its own degradation through the in-
duction of CYP24A1 gene expression in most vitamin D-respon-
sive tissues [1]. However, the phenotype of markedly enhanced
1,25D levels, severe hypercalcaemia and nephrocalcinosis in
the Cyp24a1-null mice [5], underscored not only the importance
of CYP24A1 in preventing vitamin D toxicity, but also that 1,25D
suppression of its own synthesis had little, if any, pathophysio-
logical relevance to prevent elevations in serum 1,25D above
normal levels.
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Recently, several loss-of-function mutations of the CYP24A1
gene were identiﬁed [6–11] with a very low frequency in the gen-
eral population of 0.06% for the pathogenic pE143del mutation
initially described by Schlingmann [11]. A more recent report
based on single nucleotide polymorphisms estimated, however,
the frequency of predicted bi-allelic mutations of CYP24A1 in
the general population to be as high as 4–20% [9]. Regardless
of their actual frequency, these mutations were sufﬁcient to
cause infantile hypercalcaemia in children [6–11], followed by a
long-lasting history of hypercalcaemic episodes and kidney stone
formation [6–11], which could eventually progress to nephrocal-
cinosis and renal insufﬁciency, as described in this case report.
The absence of concurrent primary hyperparathyroidism,
malignancy or a granulomatous disorder (sarcoidosis or tubercu-
losis) exacerbating 1,25D production and hypercalcaemia in
individuals carrying the CYP24A1 mutation has conclusively
corroborated the essential role of CYP24A1 in 1,25D degradation
demonstrated in the Cyp24a1-null mice. Furthermore, the hyper-
calcaemia of tuberculosis and several granulomatoses results not
only from γ-interferon induction of macrophage 1,25D produc-
tion but also from γ-interferon impairment of 1,25D induction
of CYP24A1 expression. Indeed, physical interactions of the
DNA binding site of the VDRwith Stat1, the protein thatmediates
γ-interferon signalling, impede 1,25D–VDR binding to theCYP24A1
gene promoter to induce transcription [12, 13].
Not every hospital has the resources for genetic analyses to
conclusively identify a CYP24A1mutation. However, the concur-
rence of persistent hypercalcaemia, hypercalciuria, suppressed
parathyroid hormone (PTH), and elevated serum 1,25D levels,
with normal or mildly elevated 25D in the absence of any malig-
nancy or granulomatous disorder, shouldmake a clinician suspi-
cious of this rare disorder and ready to implement the best
therapeutic strategy to avoid persistent hypercalcaemia and pre-
vent disease progression to nephrocalcinosis or renal damage.
Important considerations to improve current strategies are that
some patients with inactivating CYP24A1 mutations responded
to ketoconazole but not to corticosteroids [6] and also the wor-
sening of the hypercalcaemic episodes upon elevations in the
dosage of hydrochlorothiazide [6].
The cytochrome P450 inhibitor ketoconazole has been used
alone or in combination with corticosteroids to attenuatemacro-
phage 1,25D production and hypercalcaemia in granulomatous
disorders [14]. Indeed, in some of the newly reported cases of
Cyp24a1-inactivatingmutations, ketoconazole administration ef-
fectively lowered serum1,25D and calcium levels. However, there
is concern about the potential renal and hepatic toxicity of the
high doses of ketoconazole required and also in a prolonged dur-
ation of treatment with ketoconazole for persistent hypercalcae-
mia. An important contribution of this case report is that it
presents ﬂuconazole as a potentially safer alternative to ketocon-
azole to attenuate 1,25D synthesis and effectively correct hyper-
calcaemia in this rare disorder.
Another important consideration to improve therapy is that
the incidence of hypercalcaemic episodes in patients with
CYP24A1mutations also associatedwith periods of higher expos-
ure to sunlight [8]. This could be explained in part by the de-
scribed synergy between 25D and 1,25D for VDR activation, as
sunlight exposure will increase circulating vitamin D levels that
will be converted to 25D by the loosely regulated CYP27A1 and
CYP2R1 enzymes. In this case report, the patient was instructed
to avoid tanning beds.
Theoretically, inhibition of vitamin D conversion to 25D should
help attenuate the hypercalcaemic episodes following sunlight
exposure or vitamin D supplementation. One well-recognized
Fig. 1. Systemic and local vitamin D bioactivation and actions. Genetic inactivation of the CYP24A1 gene (red X) compromises the tightly controlled balance between
synthesis and catabolism increasing serum and intracellular 1,25D and 25D levels. These elevations cause hypercalcaemia by simultaneous exacerbation of 1,25D/
VDR calcitropic actions, 25D/1,25D synergy for VDR activation and direct 25D activation of the VDR. Interventions with ketoconazole (KC) and ﬂuconazole (FC) or
phenobarbital (PB) should effectively inhibit 25D and 1,25D syntheses through a direct targeting of the key converting enzymes.


























inhibitor of vitamin D conversion to 25D is the antiepileptic drug
phentobarbital [15] suggesting its potential as a co-adjuvant to
ketoconazole, or the safer ﬂuconazole, to expand the therapeutic
strategy to target simultaneously vitamin D conversion to 25D
and 25D conversion to 1,25D.
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